Mark Tompkins
Angel Investor
New York, United States
Mark Tompkins is a funding round investor in New York focused on Mobile and Sensor. Mark Tompkins has served as the senior financial officer at several large companies.Mark was Senior Vice President and Chief Financial Officer of Innovene, a petroleum refining and chemical polymer business and subsidiary of BP, from May 2005 to January 2006, when Innovene was sold to a strategic buyer. From 2001 to 2005 Tompkins was SeniorVice President and Chief Financial Officer of Vulcan Materials Company, a publicly traded construction materials and chemicals company. From 1998 to 2001, Mark N Tompkins was Senior Vice President and Chief Financial Officer of Chemtura Corporation (formerly Great Lakes Chemical Corporation), a publicly traded specialty chemicals company. From 1996 to 1998, he was Vice President of Finance and Business Development for the polymers division, and Vice President of Finance and Business Development for the electronic materials division of Honeywell Corporation. From 1990 to 1996, Mark worked at Monsanto Company in various management level finance and accounting positions, including Chief Financial Officer of the growth enterprises division.Mark received a BS in business, with majors in finance and management, and an MBA from Eastern Illinois University. Mark is a CPA, and a director of W.R. Grace & Co., and CVR Energy Inc. Mark N Tompkins is also Associate Professor at the Department of Political Science, University of South Carolina.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Mark Tompkins invests in
Stages Mark Tompkins invests in
Countries Mark Tompkins invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Mobile 1 (20%)
- Sensor 1 (20%)
- Genetics 1 (20%)
- Robotics 1 (20%)
- Wireless 1 (20%)
Stage
- Funding Round 2 (40%)
- Angel 1 (20%)
- Private Equity 1 (20%)
- Venture - Series Unknown 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Serve Robotics provides a delivery platform that integrates self-driving hardware, autonomy software, and fleet operations to move goods safely on sidewalks and pedestrian areas. Its robots are built to interact with urban environments, navigate around people and obstacles, and complete contactless deliveries for restaurants and delivery platforms.Serve Robotics partners with food delivery services and local merchants to support neighborhood-based delivery workflows while reducing dependence on cars. | $30M / Aug 10, 2023 | ||
| Guerrilla RF is a fabless semiconductor company providing high performance, differentiated products. With a strong background in Wi-Fi discrete MMIC's, the Wi-Fi Access Point market is the initial target market for their products. They design and sell the absolute best in class high-performance RF and Microwave IC's, enabling new levelsof performance, range, and coverage in wireless systems. Through patented technology and deep domain expertise, Guerrilla RF addresses the ignored and unmet performance and functionality you need.Guerrilla RF was founded in 2013 and is headquartered in Greensboro, North Carolina, United States. | $4.4M / Angel / Nov 17, 2021 | ||
| Aeluma operates as a semiconductor company that specializes in sensors and communications. | Private Equity / Jul 01, 2021 | ||
| Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $20M / Venture - Series Unknown / Sep 27, 2017 | ||
| See all 5 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Mark Tompkins invest in?
Mark Tompkins invests primarily in Mobile, Sensor and Genetics startups, most often at Funding Round and Angel stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mark Tompkins?
Public channels for Mark Tompkins include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Mark Tompkins last invest?
The most recent investment recorded for Mark Tompkins closed in Aug 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
